Search hospitals > Kansas > Pittsburg

Ascension Via Christi - Pittsburg

Claim this profile
Pittsburg, Kansas 66762
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
134 reported clinical trials
18 medical researchers
Photo of Ascension Via Christi - Pittsburg in PittsburgPhoto of Ascension Via Christi - Pittsburg in PittsburgPhoto of Ascension Via Christi - Pittsburg in Pittsburg

Summary

Ascension Via Christi - Pittsburg is a medical facility located in Pittsburg, Kansas. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Ascension Via Christi - Pittsburg is involved with conducting 134 clinical trials across 394 conditions. There are 18 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.

Area of expertise

1Cancer
Global Leader
Ascension Via Christi - Pittsburg has run 65 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Ascension Via Christi - Pittsburg has run 24 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Ascension Via Christi - Pittsburg

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Carcinoma
Cancer
Bladder Cancer
Renal Cell Carcinoma
Squamous Cell Carcinoma
Pancreatic Cancer
Tumors
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Ascension Via Christi - Pittsburg?
Ascension Via Christi - Pittsburg is a medical facility located in Pittsburg, Kansas. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Ascension Via Christi - Pittsburg is involved with conducting 134 clinical trials across 394 conditions. There are 18 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.